The European contract research organisation JSW – Research and the Japanese biotech company Trans Genic Inc. started joint marketing activities with the beginning of 2006.
JSW Research is an Austrian contract research organisation offering preclinical and clinical research services. Offering comprehensive in vitro and in vivo models for drug development and target validation in preclinical research, the Austrian partner focuses on neurodegeneration as it appears in Alzheimer’s, Parkinson’s Disease, Stroke and other CNS impairments.
Trans Genic Inc. is a TSE (Tokyo Stock Exchange) listed company that offers various knock out mice as well as a broad range of high affinity antibodies for bioresearch.
Trans Genic Inc. will represent the European CRO on the Japanese market. Consequently customers in Japan will have highly competent local executives carefully considering specific requirements.
The in vitro product range comprises various cell culture based and cell free mostly neurodegeneration related model systems. Furthermore there are several transgenic and non-transgenic in vivo models available. Biochemical, molecular and cell biological as well as histological and behavioral approaches routinely used for evaluations represent a broad spectrum of methods available for effective drug developments or target validations.
The preclinical research groups are well qualified for in-depth analyses of specific topics like amyloid pathology, signal transduction pathways and others.
In clinical research a global network including excellent contacts to the United States of America, the European Community, Eastern Europe and Asia facilitates the launch of research projects in all clinical phases worldwide. Additionally innovative tools like electronic data capture, web-based randomizing and others are available. The clinical research team is experienced in various frequent and less frequent indications.
A well designed and repeatedly certified quality assurance system as well as the close collaboration between JSW – Research and Trans Genic Inc. will ensure an optimal performance in all contract research projects that are expected to be started on the promising Japanese market.
JSW Research is an Austrian contract research organisation offering preclinical and clinical research services. Offering comprehensive in vitro and in vivo models for drug development and target validation in preclinical research, the Austrian partner focuses on neurodegeneration as it appears in Alzheimer’s, Parkinson’s Disease, Stroke and other CNS impairments.
Trans Genic Inc. is a TSE (Tokyo Stock Exchange) listed company that offers various knock out mice as well as a broad range of high affinity antibodies for bioresearch.
Trans Genic Inc. will represent the European CRO on the Japanese market. Consequently customers in Japan will have highly competent local executives carefully considering specific requirements.
The in vitro product range comprises various cell culture based and cell free mostly neurodegeneration related model systems. Furthermore there are several transgenic and non-transgenic in vivo models available. Biochemical, molecular and cell biological as well as histological and behavioral approaches routinely used for evaluations represent a broad spectrum of methods available for effective drug developments or target validations.
The preclinical research groups are well qualified for in-depth analyses of specific topics like amyloid pathology, signal transduction pathways and others.
In clinical research a global network including excellent contacts to the United States of America, the European Community, Eastern Europe and Asia facilitates the launch of research projects in all clinical phases worldwide. Additionally innovative tools like electronic data capture, web-based randomizing and others are available. The clinical research team is experienced in various frequent and less frequent indications.
A well designed and repeatedly certified quality assurance system as well as the close collaboration between JSW – Research and Trans Genic Inc. will ensure an optimal performance in all contract research projects that are expected to be started on the promising Japanese market.
